Enhancement of Oral Bioavailability of E804 by Self-Nanoemulsifying Drug Delivery System (SNEDDS) in Rats

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3792-3799

  Heshmati, Nasim ^a   Cheng, Xinlai ^a   Eisenbrand, Gerhard ^b   Fricker, Gert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

Author keywords

Bioavailability; Drug delivery; E804; Excipients; Formulation; Indirubin; Self nanoemulsifying drug delivery system (SNEDDS); Solubility

Indexed keywords

INDIRUBIN; INDIRUBIN 3' OXIME 2,3 DIHYDROXYPROPYL ETHER; MACROGOL 400; OCTANOIN; SOLUTOL HS 15; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FREEZE THAWING; MALE; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; SUSPENSION;

BIOAVAILABILITY; DRUG DELIVERY; EXCIPIENTS; FORMULATION; INDIRUBIN; E804; SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM (SNEDDS); SOLUBILITY;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; INDOLES; MALE; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; STEARIC ACIDS; SUSPENSIONS; WATER;

EID: 84883759426     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23696     Document Type: Article

References (48)

1. Tang W, Eisenbrand G. 1992. Chinese drugs of plant origin: Chemistry, pharmacology, and use in traditional and modern medicine. Springer-Verlag, Berlin.
2. Zheng QT, Lu DJ, Yang SL. 1979. Pharmacological studies of indirubin. I. Antitumor effect. Comm Chin Herb Med 10:35-39.
3. Zheng QT, Qi SB, Cheng ZY. 1979. Pharmacologic studies of indirubin. II. Absorption distribution and exeretion of 3H indirubin. Comm Chin Herb Med 10:19-21.
4. Wu GY, Fang FD, Liu JZ, Chang A, Ho YH. 1980. Studies on the mechanism of action of indirubin in the treatment of chronic granulocytic leukemia. I. Effects on nucleic acid and protein synthesis in human leukemic cells. Chin Med J 60:451-454.
5. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. 1999. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1(1):60-67.
6. Marko D, Schatzle S, Friedel A, Genzlinger A, Zankl H, Meijer L, Eisenbrand G. 2001. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 84(2):283-289.
7. Perabo FG, Frossler C, Landwehrs G, Schmidt DH, von Rucker A, Wirger A, Muller SC. 2006. Indirubin-3′-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res 26(3A):2129-2135.
8. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. 2001. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: Induction of endoreplication following prophase arrest. Oncogene 20(29):3786-3797.
9. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. 2004. Molecular mechanisms of indirubin and its derivatives: Novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 130(11):627-635.
10. Li C, Go Y, Mao Z, Koyano K, Kai Y, Kanehisa N, Zhu Q, Zhou Z, Wu S. 1996. The synthesis, antileukemic activity, and crystal structures of indirubin derivatives. Bull Chem Soc Jpn 69:1621-1627.
11. Sridhar J, Akula N, Pattabiraman N. 2006. Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J 8(1):E204-E221.
12. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. 2005. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102(17):5998-6003.
13. Nam S, Scuto A, Yang F, Chen W, Park S, Yoo HS, Konig H, Bhatia R, Cheng X, Merz KH, Eisenbrand G, Jove R. 2012. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol 6(3):276-283.
14. Patel J, Kevin G, Patel A, Raval M, Sheth N. 2011. Design and development of a self-nanoemulsifying drug delivery system for telmisartan for oral drug delivery. Int J Pharm Investig 1(2):112-118.
15. Zhao Y, Wang C, Chow AH, Ren K, Gong T, Zhang Z, Zheng Y. 2010. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: Formulation and bioavailability studies. Int J Pharm 383(1-2):170-177.
16. Thomas N, Holm R, Mullertz A, Rades T. 2012. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release 160(1):25-32.
17. Thomas N, Holm R, Garmer M, Karlsson JJ, Mullertz A, Rades T. 2013. Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J 15(1):219-227.
18. Patel AR, Vavia PR. 2007. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J 9(3):E344-352.
19. Villar AM, Naveros BC, Campmany AC, Trenchs MA, Rocabert CB, Bellowa LH. 2012. Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil. Int J Pharm 431(1-2):161-175.
20. Patel J, Patel A, Raval M, Sheth N. 2011. Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan. J Adv Pharm Technol Res 2(1):9-16.
21. Borhade V, Nair H, Hegde D. 2008. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech 9(1):13-21.
22. Ghosh PK, Murthy RS. 2006. Microemulsions: A potential drug delivery system. Curr Drug Deliv 3(2):167-180.
23. Kyatanwar AU, Jadhav KR, Kadam VJ. 2010. Self micro-emulsifying drug delivery system (SMEDDS): Review. J Pharm Res 3(2):75-83.
24. Porter CJ, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6(3):231-248.
25. Porter CJ, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 50 Suppl 1:S127-S147.
26. Shen HZ, Ming Kang 2006. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol 58:1183-1191.
27. Pouton CW. 1985. Self-emulsifying drug delivery systems: Assessment of the efficiency of emulsification. Int J Pharm 27(2-3):335-348.
28. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. 1998. Formulationdesign and bioavailabilityassessment of lipidicself-emulsifyingformulations of halofantrine. Int J Pharm 167(1-2):155-164.
29. Zhang P, Liu Y, Feng N, Xu J. 2008. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm 355(1-2):269-276.
30. Anton N, Vandamme TF. 2011. Nano-emulsions and micro-emulsions: Clarifications of the critical differences. Pharm Res 28(5):978-985.
31. Constantinides PP. 1995. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res 12(11):1561-1572.
32. Dixit AR, Rajput SJ, Patel SG. 2010. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech 11(1):314-321.
33. Pouton CW, Porter CJ. 2008. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev 60(6):625-637.
34. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21(2):201-230.
35. Amani A, York P, Waard H, Anwar J. 2011. Molecular dynamics simulation of a plysorbate 80 micelle in water. Soft Matter 7:2900-2908.
36. Baki A, Cullen D, Sephton M, Sims M. 2010. Aqueous solvents for hydrocarbons and other hydrophobic compounds. google patents, B01F17/00 ed.
37. Rowe RC, Sheskey PJ, Quinn ME. 2009. Handbook of pharmaceutical excipients. 6th ed. Washington; London, UK: Pharmaceutical Press.
38. Maupas C, Moulari B, Beduneau A, Lamprecht A, Pellequer Y. 2011. Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells. Int J Pharm 411(1-2):136-141.
39. Malvern Instrument Ltd. 2006. Surfactant micelle characterization using dynamic light scattering. Worcestershire, UK: Malvern Instrument Ltd.
40. Ruchatz F, Schuch H. 1998. Physicochemical properties of Solutol HS 15 and its solubilizates. In BASF ExAct ed. Ludwigshafen, Germany.
41. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45(1):89-121.
42. Rajebahadur M, Zia H, Nues A, Lee C. 2006. Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15. Drug Deliv 13(3):201-206.
43. Thomas N, Mullertz A, Graf A, Rades T. 2012. Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems. J Pharm Sci 101(5):1721-1731.
44. Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK, Mukherjee R. 2009. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). AAPS PharmSciTech 10(3):906-916.
45. Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP. 2012. Improved oral bioavailability of poorly water-soluble indirubin by a supersaturatable self-microemulsifying drug delivery system. Int J Nanomed 7:1115-1125.
46. Mullertz A, Ogbonna A, Ren S, Rades T. 2010. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 62(11):1622-1636.
47. Jiao J. 2008. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev 60(15):1663-1673.
48. Dannenfelser RM, Liu R, Li S. 2008. Micellization and drug solubility enhancement. In Water-insoluble drug formulation; Liu R, Ed. 2nd ed. CRC Press, Taylor & Francis Group, LLC., p 669.